Yoshiro Saito

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5587635/publications.pdf

Version: 2024-02-01

84 papers	3,754 citations	134610 34 h-index	150775 59 g-index
86 all docs	86 docs citations	86 times ranked	4871 citing authors

#	Article	IF	Citations
1	Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors. Drug Metabolism and Pharmacokinetics, 2022, 43, 100441.	1.1	2
2	Phosphatidylcholine (18:0/20:4), a potential biomarker to predict ethionamideâ€induced hepatic steatosis in rats. Journal of Applied Toxicology, 2022, 42, 1533-1547.	1.4	3
3	Lipidomic Analysis of Extracellular Vesicles Isolated from Human Plasma and Serum. Methods in Molecular Biology, 2022, 2504, 157-173.	0.4	1
4	2021 White Paper on Recent Issues in Bioanalysis: ISR for Biomarkers, Liquid Biopsies, Spectral Cytometry, Inhalation/Oral & Multispecific Biotherapeutics, Accuracy/LLOQ for Flow Cytometry (<u>Part 2</u> â€“ Recommendations on Biomarkers/CDx Assays Development & Validation,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	14
5	2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory InputsÂ(<u>Part 1A</u>â€“ Recommendations on Endogenous Compounds, Small Molecules,) Tj ETQq1 1 0.784314 rgBT /C	0.6	14
6	Bioanalysis of therapeutic monoclonal antibody by peptide adsorption-controlled LCâ€“MS. Bioanalysis, 2021, 13, 265-276.	0.6	2
7	Implementation of Pharmacogenomic Information on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Frontiers in Medicine, 2021, 8, 644154.	1.2	2
8	Analytical method validation for biomarkers as a drug development tool: points to consider. Bioanalysis, 2021, 13, 1379-1389.	0.6	9
9	Plasma Lipid Profiling of Three Types of Drug-Induced Liver Injury in Japanese Patients: A Preliminary Study. Metabolites, 2020, 10, 355.	1.3	10
10	Association of HLA-DRB1*04:05 allele with drug-induced interstitial lung disease in Japanese population. Pharmacogenomics Journal, 2020, 20, 823-830.	0.9	8
11	Hepatic Adaptation to Therapeutic Doses of Acetaminophen: An Exploratory Study in Healthy Individuals. Clinical Therapeutics, 2020, 42, 1276-1291.e1.	1.1	6
12	Generic MS-based method for the bioanalysis of therapeutic monoclonal antibodies in nonclinical studies. Bioanalysis, 2020, 12, 231-243.	0.6	9
13	Association of HLA-A*11:01 with Sulfonamide-Related Severe Cutaneous Adverse Reactions in Japanese Patients. Journal of Investigative Dermatology, 2020, 140, 1659-1662.e6.	0.3	18
14	Overall Similarities and a Possible Factor Affecting Plasma Metabolome Profiles Between Venous and Capillary Blood Samples From 20 Healthy Human Males. Journal of Pharmaceutical Sciences, 2019, 108, 3737-3744.	1.6	2
15	Lipid Profile Characterization and Lipoprotein Comparison of Extracellular Vesicles from Human Plasma and Serum. Metabolites, 2019, 9, 259.	1.3	49
16	Lipidomic signatures of aortic media from patients with atherosclerotic and nonatherosclerotic aneurysms. Scientific Reports, 2019, 9, 15472.	1.6	8
17	Comprehensive lipid profiling of bleomycinâ€induced lung injury. Journal of Applied Toxicology, 2019, 39, 658-671.	1.4	14
18	Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan. Bioanalysis, 2019, 11, 55-60.	0.6	3

#	Article	IF	Citations
19	Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and handâ€“foot skin reactions in sorafenib-treated patients. Cancer Chemotherapy and Pharmacology, 2018, 82, 677-684.	1.1	20
20	Ether-phosphatidylcholine characterized by consolidated plasma and liver lipidomics is a predictive biomarker for valproic acid-induced hepatic steatosis. Journal of Toxicological Sciences, 2018, 43, 395-405.	0.7	10
21	Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population. Drug Metabolism and Pharmacokinetics, 2018, 33, 141-149.	1.1	2
22	Arachidonic acid-containing phosphatidylcholine characterized by consolidated plasma and liver lipidomics as an early onset marker for tamoxifen-induced hepatic phospholipidosis. Journal of Applied Toxicology, 2017, 37, 943-953.	1.4	17
23	Enrichment of resolving power improves ion-peak quantification on a lipidomics platform. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1055-1056, 20-28.	1.2	15
24	Plasma Lipidomics of Healthy Japanese Adults Reveals Gender- and Age-Related Differences. Journal of Pharmaceutical Sciences, 2017, 106, 2914-2918.	1.6	8
25	Evaluation of the Potential Risk of Drugs to Induce Hepatotoxicity in Humanâ€”Relationships between Hepatic Steatosis Observed in Non-Clinical Toxicity Study and Hepatotoxicity in Humans-. International Journal of Molecular Sciences, 2017, 18, 810.	1.8	15
26	Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma. Scientific Reports, 2016, 6, 28932.	1.6	100
27	The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 1165-1170.	1.1	13
28	Gender- and Age-Associated Differences in Serum Metabolite Profiles among Japanese Populations. Biological and Pharmaceutical Bulletin, 2016, 39, 1179-1186.	0.6	41
29	Plasma lipid profiling of different types of hepatic fibrosis induced by carbon tetrachloride and lomustine in rats. Lipids in Health and Disease, 2016, 15, 74.	1.2	16
30	Plasma Lipid Profiling of Patients with Chronic Ocular Complications Caused by Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. PLoS ONE, 2016, 11, e0167402.	1.1	5
31	Cross-Classification of Human Urinary Lipidome by Sex, Age, and Body Mass Index. PLoS ONE, 2016, 11, e0168188.	1.1	13
32	Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method. BMC Cancer, 2015, 15, 718.	1.1	11
33	IKZF1, a new susceptibility gene for cold medicineâ€“related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. Journal of Allergy and Clinical Immunology, 2015, 135, 1538-1545.e17.	1.5	55
34	Hydrocortisone enhances the barrier properties of HBMEC/ciÎ², a brain microvascular endothelial cell line, through mesenchymal-to-endothelial transition-like effects. Fluids and Barriers of the CNS, 2015, 12, 7.	2.4	31
35	Plasma and Serum Lipidomics of Healthy White Adults Shows Characteristic Profiles by Subjectsâ€™ Gender and Age. PLoS ONE, 2014, 9, e91806.	1.1	161
36	Application of a Combination of a Knowledge-Based Algorithm and 2-Stage Screening to Hypothesis-Free Genomic Data on Irinotecan-Treated Patients for Identification of a Candidate Single Nucleotide Polymorphism Related to an Adverse Effect. PLoS ONE, 2014, 9, e105160.	1.1	5

#	Article	IF	Citations
37	Differences in metabolite profiles between blood matrices, ages, and sexes among Caucasian individuals and their inter-individual variations. Metabolomics, 2014, 10, 402-413.	1.4	30
38	Glucosylceramide and Lysophosphatidylcholines as Potential Blood Biomarkers for Drug-Induced Hepatic Phospholipidosis. Toxicological Sciences, 2014, 141, 377-386.	1.4	31
39	Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. Scientific Reports, 2014, 4, 4862.	1.6	83
40	Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimerâ€™s disease. Lipids in Health and Disease, 2013, 12, 68.	1.2	120
41	Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data. Journal of Bioscience and Bioengineering, 2013, 116, 768-773.	1.1	8
42	Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. Journal of Human Genetics, 2013, 58, 317-326.	1.1	68
43	Specific HLA types are associated with antiepileptic drug-induced Stevensâ€“Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics, 2013, 14, 1821-1831.	0.6	60
44	Plasma and Serum from Nonfasting Men and Women Differ in Their Lipidomic Profiles. Biological and Pharmaceutical Bulletin, 2013, 36, 682-685.	0.6	37
45	Influence of CYP2C8*13 and CYP2C8*14 Alleles on Amiodarone Nâ€Deethylation. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 359-362.	1.2	9
46	Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 967-988.	1.5	21
47	Genetic variations of orosomucoid genes associated with serum alphaâ€1â€acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer. Journal of Pharmaceutical Sciences, 2011, 100, 4546-4559.	1.6	10
48	Genome-Wide Association Study on Overall Survival of Advanced Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel. Journal of Thoracic Oncology, 2011, 6, 132-138.	0.5	54
49	Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemotherapy and Pharmacology, 2010, 66, 95-105.	1.1	55
50	Functional Characterization of CYP2C8.13 and CYP2C8.14: Catalytic Activities toward Paclitaxel. Basic and Clinical Pharmacology and Toxicology, 2010, 107, 565-569.	1.2	15
51	Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. British Journal of Clinical Pharmacology, 2010, 70, 222-233.	1.1	44
52	CYP3A4*16andCYP3A4*18Alleles Found in East Asians Exhibit Differential Catalytic Activities for Seven CYP3A4 Substrate Drugs. Drug Metabolism and Disposition, 2010, 38, 2100-2104.	1.7	45
53	Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients. Clinical Pharmacokinetics, 2010, 49, 549-558.	1.6	43
54	Close Association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 Haplotype and Its Apparent Influence on 7-Ethyl-10-hydroxycamptothecin (SN-38) Glucuronidation in Japanese. Drug Metabolism and Disposition, 2009, 37, 272-276.	1.7	25

#	Article	IF	Citations
55	Ethnic Differences of two Non-synonymous Single Nucleotide Polymorphisms in CDA Gene. Drug Metabolism and Pharmacokinetics, 2009, 24, 553-556.	1.1	34
56	Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemotherapy and Pharmacology, 2008, 62, 529-537.	1.1	22
57	Importance of UDP-glucuronosyltransferase 1A1âˆ—6 for irinotecan toxicities in Japanese cancer patients. Cancer Letters, 2008, 261, 165-171.	3.2	43
58	Genetic Variations and Haplotypes of ABCC2 Encoding MRP2 in a Japanese Population. Drug Metabolism and Pharmacokinetics, 2008, 23, 139-147.	1.1	24
59	A Combinatorial Haplotype of the UDP-Glucuronosyltransferase 1A1 Gene (#60-#IB) Increases Total Bilirubin Concentrations in Japanese Volunteers. Clinical Chemistry, 2007, 53, 356-358.	1.5	11
60	Haplotypes and a Novel Defective Allele of CES2 Found in a Japanese Population. Drug Metabolism and Disposition, 2007, 35, 1865-1872.	1.7	26
61	Pharmacokinetics of Gemcitabine in Japanese Cancer Patients: The Impact of a Cytidine Deaminase Polymorphism. Journal of Clinical Oncology, 2007, 26, 32-42.	0.8	168
62	Genetic Variations and Frequencies of Major Haplotypes in SLCO1B1 Encoding the Transporter OATP1B1 in Japanese Subjects: SLCO1B1*17 is More Prevalent Than *15. Drug Metabolism and Pharmacokinetics, 2007, 22, 456-461.	1.1	29
63	Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenetics and Genomics, 2007, 17, 497-504.	0.7	259
64	CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenetics and Genomics, 2007, 17, 461-471.	0.7	24
65	Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. Journal of Human Genetics, 2007, 52, 804-819.	1.1	51
66	Genetic Variation and Haplotype Structure of the ABC Transporter Gene ABCG2 in a Japanese Population. Drug Metabolism and Pharmacokinetics, 2006, 21, 109-121.	1.1	41
67	Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clinical Pharmacology and Therapeutics, 2006, 80, 179-191.	2.3	31
68	Sequence-based Analysis of the CYP2D6*36-CYP2D6*10 Tandem-type Arrangement, a Major CYP2D6*10 Haplotype in the Japanese Population. Drug Metabolism and Pharmacokinetics, 2006, 21, 208-216.	1.1	30
69	Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus Cisplatin. Clinical Cancer Research, 2005, 11, 2620-2624.	3.2	85
70	FUNCTIONAL CHARACTERIZATION OF THREE NATURALLY OCCURRING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE CES2 GENE ENCODING CARBOXYLESTERASE 2 (HCE-2). Drug Metabolism and Disposition, 2005, 33, 1482-1487.	1.7	47
71	FUNCTIONAL CHARACTERIZATION OF FIVE NOVEL CYP2C8 VARIANTS, G171S, R186X, R186G, K247R, AND K383N, FOUND IN A JAPANESE POPULATION. Drug Metabolism and Disposition, 2005, 33, 630-636.	1.7	49
72	Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metabolism and Disposition, 2005, 33, 1905-10.	1.7	25

#	Article	IF	Citations
73	RACIAL VARIABILITY IN HAPLOTYPE FREQUENCIES OF UGT1A1 AND GLUCURONIDATION ACTIVITY OF A NOVEL SINGLE NUCLEOTIDE POLYMORPHISM 686C> T (P229L) FOUND IN AN AFRICAN-AMERICAN. Drug Metabolism and Disposition, 2005, 33, 458-465.	1.7	149
74	Ethnic Differences in Genetic Polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metabolism and Pharmacokinetics, 2004, 19, 83-95.	1.1	144
75	Six Novel Nonsynonymous CYP1A2 Gene Polymorphisms: Catalytic Activities of the Naturally Occurring Variant Enzymes. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 300-306.	1.3	81
76	Haplotypes ofCYP3A4 and their close linkage withCYP3A5 haplotypes in a Japanese population. Human Mutation, 2004, 23, 100-100.	1.1	140
77	UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer*1. Clinical Pharmacology and Therapeutics, 2004, 75, 501-515.	2.3	243
78	Single nucleotide polymorphisms and haplotype frequencies ofCYP3A5 in a Japanese population. Human Mutation, 2003, 21, 653-653.	1.1	60
79	Glucuronidation of 7-Ethyl-10-hydroxycamptothecin (SN-38), an Active Metabolite of Irinotecan (CPT-11), by Human UGT1A1 Variants, G71R, P229Q, and Y486D. Drug Metabolism and Disposition, 2003, 31, 108-113.	1.7	108
80	Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics and Genomics, 2003, 13, 741-757.	5.7	141
81	CYP3A4 Gene Polymorphisms Influence Testosterone 6Î²-hydroxylation. Drug Metabolism and Pharmacokinetics, 2002, 17, 150-156.	1.1	55
82	Five Novel Single Nucleotide Polymorphisms in the CYP2C8 Gene, One of which Induces a Frame-shift. Drug Metabolism and Pharmacokinetics, 2002, 17, 374-377.	1.1	52
83	Non-synonymous Single Nucleotide Alterations Found in the CYP2C8 Gene Result in Reduced in Vitro Paclitaxel Metabolism.. Biological and Pharmaceutical Bulletin, 2001, 24, 1427-1430.	0.6	103
84	Apparent Low Frequency of Sequence Variability within the Proximal Promoter Region of the Cytochrome P450 (CYP) 3A5 Gene in Established Cell Lines from Japanese Individuals.. Biological and Pharmaceutical Bulletin, 2001, 24, 954-957.	0.6	12